Chondrogard 100 mg/ml solution for intramuscular injection for intra-articular injection 2 ml ampoules 25 pcs.

• Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of peripheral joints;

• intervertebral osteochondrosis and osteoarthritis.

• to accelerate the formation of callus in fractures.

The drug is administered intramuscularly at a dose of 100 mg every other day. With good tolerance, the dose is increased to 200 mg starting from the fourth injection.
The treatment course consists of 25-30 injections. If necessary, a repeat treatment course may be conducted after 6 months.
In cases of osteoarthritis of large joints, a combination of intra-articular and intramuscular administration methods is possible.
Up to 5 intra-articular injections of 200 mg are performed with a 3-day interval between injections and 16 intramuscular injections of 200 mg with a 1-day interval between injections (every other day).
Intra-articular administration of the drug is carried out under aseptic conditions by a specialist trained in the technique of intra-articular injection.
Depending on the size of the joint, up to 2 ml of the CHONDROGARD® preparation can be injected into the joint cavity.
After intra-articular administration of the drug, the injection site is treated with an alcohol swab and a bactericidal plaster is applied.
To form a bone callus, the treatment course lasts 3-4 weeks (10-14 intramuscular injections every other day).

Composition per 1 ampoule:
active ingredient: sodium chondroitin sulfate - 100 mg;
excipients: benzyl alcohol - 9.0 mg; sodium metabisulfite - 1.0 mg; sodium hydroxide to pH 6.0-7.5; water for injection to 1.0 ml

A clear, colorless solution or slightly yellowish in hue with a scent of benzyl alcohol.

• increased sensitivity to the drug or its components;

• bleeding and tendency to bleed;

• thrombophlebitis;

• for intra-articular administration: presence of active inflammatory or infectious processes in the joint, presence of active skin disease or skin infection in the area of the intended injection;

• pediatric age;

• pregnancy and lactation (data on the safety of the drug's use are currently unavailable).

Use in Pediatrics
Data on the efficacy and safety of chondroitin sulfate in children is currently unavailable.
Effect on the ability to drive vehicles and operate machinery
There is no information regarding warnings for the use of the drug by vehicle drivers and individuals working with potentially hazardous machinery.

Allergic reactions (skin itching, erythema, urticaria, dermatitis), hemorrhages at the injection site.

Currently, there have been no reported cases of chondroitin sulfate overdose.

Possible enhancement of the action of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood coagulation parameters when used together.

High molecular weight mucopolysaccharide that affects metabolic processes in hyaline cartilage.
Reduces degenerative changes in joint cartilage, accelerates its recovery processes, stimulates the synthesis of proteoglycans.
When treated with the drug, pain decreases and mobility of the affected joints improves. In the treatment of degenerative changes in joints with the development of secondary synovitis, a positive effect may be observed as early as 2-3 weeks after the start of the drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, and the range of motion in the affected joints increases. The therapeutic effect lasts for a long time after the end of the treatment course.

After intramuscular administration, chondroitin sulfate is rapidly distributed. Significant concentrations are detected in the blood within 30 minutes post-injection. The maximum concentration (Cmax) of chondroitin sulfate in plasma is reached after 1 hour, then gradually decreases over 2 days. Chondroitin sulfate accumulates primarily in the cartilage tissue of the joints. The synovial membrane does not pose a barrier to the penetration of the drug into the joint cavity.

Experiments have shown that 15 minutes after intramuscular injection, chondroitin sulfate is found in the synovial fluid, then penetrates into the articular cartilage, where its Cmax is reached after 48 hours.

With intra-articular administration, retention of chondroitin sulfate in the joint tissues is observed, along with its gradual release into the bloodstream. Following a single intra-articular administration of the drug CHONDROGARD at a dose of 200 mg, the Cmax of chondroitin sulfate in plasma is observed after 1-2 hours and ranges from 52.5 to 86.9 ng/ml, with a half-life (T1/2) of 2.5 hours.